ArticleThe Journal of clinical endocrinology and metabolism2026
Cardiovascular effects of metyrapone treatment in patients with mild autonomous cortisol secretion: a secondary analysis.
Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiovascular effects of metyrapone treatment in patients with mild autonomous cortisol secretion: a secondary analysis.The Journal of clinical endocrinology and metabolism · 2026Article
- Mild autonomous cortisol secretion (MACS) is associated with increased mortality in patients with adrenal adenomas only in the presence of type 2 diabetes: a retrospective cohort study.Cardiovascular diabetology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
contextMild autonomous cortisol secretion (MACS) is associated with increased mortality, mainly because of cardiovascular disease.
objectiveHere we investigated the effects of cortisol-lowering medical treatment on blood pressure regulation, cardiac fat depots, heart function and morphology, and other cardiovascular risk factors.
methodsIn this secondary analysis of our prospective, open-label, single-center study at the Medical University of Vienna, we investigated 15 patients with MACS (12 women; age 59 [53-64] years) before and after 12 weeks of treatment with evening doses of metyrapone (500 mg at 6 Pm and 250 mg at 10 Pm). Cardiac fat stores, morphology, and myocardial function were evaluated using cardiac magnetic resonance imaging and spectroscopy. Orthostatic blood pressure regulation was measured by standardized protocols. Lipidomics, renin-angiotensin-aldosterone-system activity and branched-chain amino acid (BCAA) concentrations were assessed.
resultsMean supine systolic (137 [121-139] vs 122 [115-129] mmHg; P = 0.041) and diastolic (89 [80-93] vs 75 [71-86] mmHg; P = .045) blood pressure decreased after treatment in patients without changes in concomitant antihypertensive medication. Epicardial fat was lower at follow-up compared to baseline (1032.70 [894.23-1482.90] vs 929.37 [736.12-1317.15] mm2; P = .022). No changes in paracardial and intramyocardial fat, as well as in cardiac function and morphology were observed. The aldosterone-to-angiotensin II ratio was lower at follow-up (1.56 [0.87-2.82] vs 1.21 [0.98-1.92]; P = .042) and alterations in lipid profiles, but not in BCAA levels, were identified.
conclusionTreatment with evening doses of metyrapone improved blood pressure and reduced epicardial adipose tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.